Veritable’s Ocular Therapeutix OCUL Stock Holding History

Veritable’s Portfolio OCUL Stock Details OCUL Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-10,000	Closed	-$93K	–	787
2017 Q1	$93K	Hold	10,000	–	–	﹤0.01%	737
2016 Q4	$84K	Buy	+10,000	New	+$77.6K	﹤0.01%	726
2016 Q3	–	Sell	-30,143	Closed	-$149K	–	740
2016 Q2	$149K	Buy	30,143 +10,143	+51%	+$100K	﹤0.01%	687
2016 Q1	$193K	Buy	+20,000	New	+$151K	0.01%	669

Other funds holding OCUL

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return

SHI

SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

CCI

Columbus Circle Investors $2.28B AUM 135.57% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Veritable's OCUL Position: Q2 2017 in Review

Veritable sold out of Ocular Therapeutix (OCUL) in Q2 2017, closing a stake of 10,000 shares — an estimated $93K sold.

Veritable first reported a position in OCUL in Q1 2016 and held it in 4 quarters. The position peaked at $193K in Q1 2016. 72 funds tracked by Wall St. Rank hold OCUL as of Q2 2017.

Veritable reported no remaining Ocular Therapeutix position as of Q2 2017 after selling out during the quarter.
Veritable sold 10,000 Ocular Therapeutix shares in Q2 2017, an estimated $93K.
Veritable first reported a position in Ocular Therapeutix in Q1 2016 and held it in 4 quarters.
Veritable's Ocular Therapeutix position peaked at $193K in Q1 2016.
72 funds tracked by Wall St. Rank held Ocular Therapeutix as of Q2 2017.

Based on Veritable's 13F filing for Q2 2017, filed 11 Aug 2017.